Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 517 participants.
Also called NCT02585778
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 517 participants
- Sponsor
- Registry
-
NCT02585778 -
2015-000799-92
-
- Other papers using this trial's data
- Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, France, Germany, Italy, Netherlands, Spain, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02585778. Randomized; double masking; primary purpose treatment. Start 2015-10-23 (actual); primary completion 2017-04-03 (actual). Results posted on 2018-05-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
- Condition
- Hypercholesterolaemia
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Lipid-Modifying Therapy (LMT)
- Intervention (Drug)
- Antihyperglycemic Drug
- Lead sponsor
- Sanofi
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct02585778- Content hash
50dab2e9f8a96a44d8cfd90acf0d8646de773ee91544e432b7845236cd2fd627